Project Grant R01DE036253
- The National Institute of Dental and Craniofacial Research awarded the University of Florida $574,966 on June 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate functional amyloid formation in Streptococcus mutans, the bacterium that causes dental caries. The research characterizes amyloid-forming proteins in S. mutans—including P1 (AGI/II), WAPA, CNM, and SMU_63—and examines how naturally occurring adhesin truncation products regulate biofilm...
- The National Institute of Dental and Craniofacial Research awarded the University of Florida $419,375 on January 16, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the roles of extracellular pyruvate in regulating Streptococcus mutans physiology and stress resistance. The project, titled "Investigating the Roles of Extracellular Pyruvate in Regulating Streptococcus Mutans Physiology and Stress Resistance," examines how the LRGAB pyruvate...
- The National Institute of Dental and Craniofacial Research awarded the University of Florida $623,879 on July 9, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate ecological approaches for caries prevention and management through prebiotic and probiotic mechanisms. The research examines how the prebiotic candidate N-acetylglucosamine modulates oral microbial diversity and biofilm metabolism to enhance anti-caries pathways expressed by health-associated...
- The National Institute of Dental and Craniofacial Research awarded the University of Florida $411,775 on July 7, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate molecular determinants of Streptococcus gordonii response to shear forces generated by fluid flow in the oral cavity. The research identifies genes involved in S. gordonii's ability to adapt to shear forces and evaluates the bacterium's gene expression in real-time in response to different levels...
- The National Institute of Dental and Craniofacial Research awarded Oregon Health & Science University $634,041 on May 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate protein interaction networks and posttranscriptional gene regulation in Streptococcus mutans, the dominant species associated with dental caries risk. The research employs a multidisciplinary approach integrating genetics, advanced mass spectrometry, next-generation sequencing,...
- The National Institute of Dental and Craniofacial Research awarded the Regents of the University of Minnesota $1.947 million on June 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate how the pioneer oral bacterium Streptococcus gordonii recognizes and responds to other early dental plaque colonizers and host factors, shaping initial biofilm community structure. The research examines the outside-in signaling circuit through which S. gordonii...
- The National Institute of Dental and Craniofacial Research, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Florida $458,877 on August 1, 2026, through the Oral Diseases and Disorders Research program (CFDA 93.121) to develop an oral vaccine targeting Fusobacterium nucleatum in oral squamous cell carcinoma. The recipient will generate a recombinant Lactobacillus gasseri expressing B-cell linear epitopes of two F. nucleatum surface...
- Federal Grant Award Summary The University of Florida received a $639,248 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded June 1, 2025, with completion scheduled for May 31, 2027. This award supports statistical methodology development and secondary analysis of the National Health and Nutrition Examination Survey (NHANES) to assess person-level marginal associations between...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded $426,250 to the University of Kansas Medical Center Research Institute, Inc. on August 14, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support basic research on pathogenic mechanisms in Streptococcus sanguinis. The two-year project, concluding August 13, 2027, will characterize two endopeptidases (SEPM homologs) encoded by this oral bacterium that can...
- The National Institute of Dental and Craniofacial Research awarded Oregon Health & Science University $524,669 on June 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate how Streptococcus sanguinis extracellular vesicles regulate gingival homeostasis and periodontal immune defense. The research explores the dual role of S. sanguinis, an early oral biofilm colonizer that both promotes oral health and exhibits pro-inflammatory traits. The project...
The National Institute of Dental and Craniofacial Research awarded the University of Florida $351,833 on August 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the functions and molecular mechanisms of protein O-phosphorylation in Streptococcus mutans, the primary bacterial agent of dental caries. The project addresses a gap in understanding how O-phosphorylation—a post-translational protein modification—regulates S. mutans adaptation and virulence in the oral environment. Preliminary phosphoproteomic analysis has revealed that O-phosphorylation affects numerous proteins critical for stress adaptation, metabolism, and cell division, yet the functional significance of these events remains largely unknown. The research pursues three specific aims: determining the functional impact of O-phosphorylation on S. mutans physiology through the first arrayed panel of phospho-mutants for any bacterial species; investigating the role of the PPPL phosphatase in cell division through a suppressor mutation analysis; and examining phosphorylation-mediated regulation of the PGF glycosylation machinery as a key virulence pathway. Performance occurs in Gainesville, Florida. The period of performance runs from August 5, 2026, through April 30, 2031. The University of Florida's Division of Sponsored Research administers the award as the recipient organization.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $351.8k | 8/6/26 |